WO1999006059A3 - Methods and compositions relating to no-mediated cytotoxicity - Google Patents

Methods and compositions relating to no-mediated cytotoxicity Download PDF

Info

Publication number
WO1999006059A3
WO1999006059A3 PCT/US1998/015781 US9815781W WO9906059A3 WO 1999006059 A3 WO1999006059 A3 WO 1999006059A3 US 9815781 W US9815781 W US 9815781W WO 9906059 A3 WO9906059 A3 WO 9906059A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
methods
diabetes
compositions
treatment
Prior art date
Application number
PCT/US1998/015781
Other languages
French (fr)
Other versions
WO1999006059A2 (en
Inventor
Hans-Ewald Hohmeier
Anice Thigpen
Guoxun Chen
Christopher B Newgard
Roger H Unger
Michio Shimabukuro
Christopher J Rhodes
Sigrun R Hugl
Sharon Cousin
Original Assignee
Univ Texas
Betagene Inc
Hohmeier Hans Ewald
Anice Thigpen
Guoxun Chen
Christopher B Newgard
Roger H Unger
Michio Shimabukuro
Christopher J Rhodes
Sigrun R Hugl
Sharon Cousin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Betagene Inc, Hohmeier Hans Ewald, Anice Thigpen, Guoxun Chen, Christopher B Newgard, Roger H Unger, Michio Shimabukuro, Christopher J Rhodes, Sigrun R Hugl, Sharon Cousin filed Critical Univ Texas
Priority to AU86717/98A priority Critical patent/AU8671798A/en
Publication of WO1999006059A2 publication Critical patent/WO1999006059A2/en
Publication of WO1999006059A3 publication Critical patent/WO1999006059A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

The present invention relates to methods and compositions for the treatment of diabetes involving free radicals. In particular, the present invention is directed to the treatment or prophylactic intervention of diabetes. The present invention demonstrates that MnSOD can play a protective role against cytokine killing, and provides strategies for engineering cell lines as islet surrogates for transplantation therapy of diabetes mellitus. Further, the present invention shows that β-cell destruction and dysfunction in adipogenic diabetes is mediated via fatty acids. Methods and compositions for ameliorating this disorder are provided herein.
PCT/US1998/015781 1997-07-30 1998-07-30 Methods and compositions relating to no-mediated cytotoxicity WO1999006059A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU86717/98A AU8671798A (en) 1997-07-30 1998-07-30 Methods and compositions relating to no-mediated cytotoxicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5509297P 1997-07-30 1997-07-30
US60/055,092 1997-07-30

Publications (2)

Publication Number Publication Date
WO1999006059A2 WO1999006059A2 (en) 1999-02-11
WO1999006059A3 true WO1999006059A3 (en) 1999-08-05

Family

ID=21995540

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015781 WO1999006059A2 (en) 1997-07-30 1998-07-30 Methods and compositions relating to no-mediated cytotoxicity

Country Status (2)

Country Link
AU (1) AU8671798A (en)
WO (1) WO1999006059A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2257284C (en) * 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
DE19921537A1 (en) * 1999-05-11 2000-11-23 Dieter Hoersch Treating carbohydrate metabolism disorders, especially diabetes, comprises activating insulin-secreting b-cells using glucagon-related peptide, glucose-dependent insulinotropic polypeptide, exendin-4 or related drugs
WO2001005943A2 (en) * 1999-07-14 2001-01-25 Betagene, Inc. Lcat recombinant cell line compositions and methods
AU2002213925A1 (en) 2000-09-18 2002-03-26 Osteometer Biotech As Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US6943001B2 (en) 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
EP1578987A2 (en) 2001-08-03 2005-09-28 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
WO2005046718A1 (en) * 2003-11-06 2005-05-26 Ohio University Diagnosis and hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in pancreas cells (12.1)
EP2896688A1 (en) * 2014-01-20 2015-07-22 Centre National de la Recherche Scientifique (CNRS) A method of producing beta pancreatic cells from progenitor cells through the use of hydrogen peroxide

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001387A1 (en) * 1985-09-03 1987-03-12 Syn-Tek Ab A superoxide dismutase
US4888358A (en) * 1988-08-25 1989-12-19 Syntex (U.S.A.) Inc. 13,14-dihydroprostaglandin C-type derivatives
WO1991018919A1 (en) * 1990-05-31 1991-12-12 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
WO1994008606A1 (en) * 1992-10-01 1994-04-28 Schering Corporation Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
WO1994014950A1 (en) * 1992-12-28 1994-07-07 Sii Technoresearch, Inc. Human variant manganese superoxide dismutase
WO1995020402A1 (en) * 1994-01-31 1995-08-03 Ludwig Institute For Cancer Research Antioxidants and intracellular glutathione raising agents for therapeutic treatments
EP0676472A1 (en) * 1987-03-14 1995-10-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Human manganese superoxide dismutase (hMn-SOD)
WO1996000790A1 (en) * 1994-06-29 1996-01-11 Rhone-Poulenc Rorer S.A. Adenovirus including a gene coding for a superoxide dismutase
JPH0812573A (en) * 1994-06-24 1996-01-16 Mitsubishi Chem Corp Free fatty acid reducing agent
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
JPH08228775A (en) * 1995-02-28 1996-09-10 Otsuka Pharmaceut Factory Inc Recombinant retrovirus vector, cell having the same vector transduced thereinto, recombinant retrovirus and t lymphocyte infected with the same virus
WO1997002004A2 (en) * 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
EP0774259A1 (en) * 1990-12-07 1997-05-21 Novartis AG New use of organic compounds
WO1997047656A1 (en) * 1996-06-13 1997-12-18 Berk Paul D Method to modulate the facilitated uptake of free fatty acids into cells by a plasma membrane fatty acid binding protein

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001387A1 (en) * 1985-09-03 1987-03-12 Syn-Tek Ab A superoxide dismutase
EP0676472A1 (en) * 1987-03-14 1995-10-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Human manganese superoxide dismutase (hMn-SOD)
US4888358A (en) * 1988-08-25 1989-12-19 Syntex (U.S.A.) Inc. 13,14-dihydroprostaglandin C-type derivatives
US5231012A (en) * 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
WO1991018919A1 (en) * 1990-05-31 1991-12-12 Schering Corporation Purification of human interleukin-4 from a secreted escherichia coli mutant
EP0774259A1 (en) * 1990-12-07 1997-05-21 Novartis AG New use of organic compounds
WO1994004680A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
WO1994008606A1 (en) * 1992-10-01 1994-04-28 Schering Corporation Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
WO1994014950A1 (en) * 1992-12-28 1994-07-07 Sii Technoresearch, Inc. Human variant manganese superoxide dismutase
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
WO1995020402A1 (en) * 1994-01-31 1995-08-03 Ludwig Institute For Cancer Research Antioxidants and intracellular glutathione raising agents for therapeutic treatments
JPH0812573A (en) * 1994-06-24 1996-01-16 Mitsubishi Chem Corp Free fatty acid reducing agent
WO1996000790A1 (en) * 1994-06-29 1996-01-11 Rhone-Poulenc Rorer S.A. Adenovirus including a gene coding for a superoxide dismutase
JPH08228775A (en) * 1995-02-28 1996-09-10 Otsuka Pharmaceut Factory Inc Recombinant retrovirus vector, cell having the same vector transduced thereinto, recombinant retrovirus and t lymphocyte infected with the same virus
WO1997002004A2 (en) * 1995-06-30 1997-01-23 Eli Lilly And Company Methods for treating diabetes
WO1997047656A1 (en) * 1996-06-13 1997-12-18 Berk Paul D Method to modulate the facilitated uptake of free fatty acids into cells by a plasma membrane fatty acid binding protein

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ARREAZA G.A. ET AL: "Interleukin-4; Potential Immunoregulatory Agent in Therapy of Insulin-Dependent Diabetes Mellitus", CLIN. IMMUNOTHER., vol. 6, no. 4, 1996, pages 251 - 260, XP002086507 *
CHEMICAL ABSTRACTS, vol. 125, no. 25, 1996, Columbus, Ohio, US; abstract no. 326040t, TOKUI M. ET AL: "Studies on the Prevention of Diabetes in NOD Mice by Intramuscular Administration of Plasmid Expressing GAD and IL-4" page 1148; XP002086509 *
DATABASE WPI Section Ch Week 9428, Derwent World Patents Index; Class B04, AN 94-234688, XP002086510 *
DATABASE WPI Section Ch Week 9612, Derwent World Patents Index; Class B03, AN 96-112633, XP002099923 *
DATABASE WPI Section Ch Week 9646, Derwent World Patents Index; Class B04, AN 96-459143, XP002086511 *
DIABETES FRONT., vol. 7, no. 4, 1996, pages 420 *
HOHMEIER. H.-E. ET AL: "Stable Expression of Manganase Superoxide Dismutase (MnSOD) in Insulinoma Cells Prevents IL-1 beta- induced Cytotoxicity and Reduces Nitric Oxide Production", J. CLIN. INVEST., vol. 101, no. 9, May 1998 (1998-05-01), pages 1811 - 1820, XP002086508 *
KALDEN J R ET AL: "BIOLOGIC AGENTS IN THE TREATMENT OF INFLAMMATORY RHEUMATIC DISEASES", CURRENT OPINION IN RHEUMATOLOGY, vol. 9, no. 3, May 1997 (1997-05-01), pages 206 - 212, XP002048556 *
MUZZIN P ET AL: "CORRECTION OF OBESITY AND DIABETES IN GENETICALLY OBESE MICE BY LEPTIN GENE THERAPY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, December 1996 (1996-12-01), pages 14804 - 14808, XP002042615 *
SHIMABUKURO M. ET AL: "Fatty Acid-Induced Beta Cell Apoptosis: A Link Between Obesity and Diabetes", PROC. NATL. ACAD. SCI. USA, vol. 95, March 1998 (1998-03-01), pages 2498 - 2502, XP002099922 *
SUTER S.L. ET AL: "Metabolic Effects of New Oral Hypoglycemic AGent CS-405 in NIDDM Subjects", DIABETES CARE, vol. 15, no. 2, 1992, pages 193 - 203, XP002099921 *

Also Published As

Publication number Publication date
AU8671798A (en) 1999-02-22
WO1999006059A2 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
TW371628B (en) Composition for treating condyloma acuminata
TW225532B (en)
EP2295063A3 (en) Compositions and the use thereof the treatment of mitochondrial diseases
TW283645B (en)
BR0214216A (en) Plant-derived or derivative material with appetite suppressant activity
GEP20022788B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
HUP0101053A2 (en) Protease inhibitors in absorbent articles
AU6915396A (en) Multiple sclerosis treatment
IE790756L (en) Cerebral therapeutic agent
WO1999006059A3 (en) Methods and compositions relating to no-mediated cytotoxicity
UA41355C2 (en) Agent for treating neuro-aids
CA2116562A1 (en) Morphogen-Induced Modulation of Inflammatory Response
MX9703693A (en) Prophylactic treatment of allergic contact dermatitis.
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
BG103780A (en) Antitussive compositions
EP1167354A3 (en) Racemic huperzine A
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
AU7000394A (en) Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
AU687906B2 (en) Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO2000071140A3 (en) Methods and compositions for modulating immune response and for the treatment of inflammatory disease
ZA935086B (en) Skin regenerating cosmetic composition
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
MD1140B1 (en) Remedy possessing a regenerative and cytoprotective activity
WO1994020115A3 (en) Hyaluronic acid used as a cancer treatment
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA